Cost analysis of the management of brain metastases in patients with advanced ALK+ NSCLC: alectinib versus crizotinib

AIM: To estimate management cost of NSCLC ALK+ patients with and without brain metastasis (BM), and to compare annual costs in patients treated with alectinib or crizotinib. METHODS: Management cost/year (€ 2018) in patients with and without BM was estimated with disaggregated resource consumption p...

Descripción completa

Detalles Bibliográficos
Autores principales: Isla, Dolores, Massuti, Bartomeu, Lázaro, Martín, de Alda, Lucía Ruiz, Gordo, Rocio, Ortega-Joaquín, Nuria, Oyagüez, Itziar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Medicine Ltd 2020
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7110588/
https://www.ncbi.nlm.nih.gov/pubmed/32256712
http://dx.doi.org/10.2217/lmt-2019-0011

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7110588/
https://www.ncbi.nlm.nih.gov/pubmed/32256712
http://dx.doi.org/10.2217/lmt-2019-0011

Ejemplares similares